Mass General Brigham Ventures

Mass General Brigham Ventures is the venture capital arm of Mass General Brigham, an integrated academic healthcare system. It invests in early-stage companies focused on innovative research and technology within the healthcare sector, with a primary mission to accelerate the translation of these advancements into commercial solutions that improve patient care.

Carl Berke

Partner

Roger Kitterman

Managing Partner

Julius Knowles

Partner

Michael Mercurio

Vice President, Physician Revenue Services

David Torchiana

President and CEO

Bhamini Vaidialingam

Associate

48 past transactions

Abcuro

Series C in 2025
Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Rippl Care

Series A in 2024
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Tuesday Health

Venture Round in 2024
Tuesday Health is a healthcare company that focuses on providing supportive care to individuals with serious illnesses. It aims to ease symptoms and reduce stress, enabling patients to spend more time at home with their loved ones. The company specializes in personalized, innovative care plans and delivers compassionate, supportive care through a value-based palliative care model.

InStride Health

Series B in 2024
InStride Health is an outpatient care platform focused on delivering evidence-based treatment for pediatric anxiety and obsessive-compulsive disorder (OCD). The company offers a tailored virtual care journey that includes individual and group therapy, coaching, and medication management. This comprehensive approach is facilitated by a coordinated team of experienced psychiatrists, therapists, and coaches, ensuring that children and teenagers receive effective and accessible care. InStride Health aims to engage young patients and their families in their treatment, making mental health support both affordable and effective.

Nocion Therapeutics

Series B in 2024
Nocion Therapeutics is a biopharmaceutical company developing novel therapies called 'nocions' that selectively target actively firing nociceptors to provide relief for serious conditions such as cough, itch, pain, and inflammation.

Abridge

Series C in 2024
Abridge is a healthcare technology company that uses generative AI to automate transcription and summarization of medical conversations. The platform turns patient-clinician discussions into structured clinical notes in real time and integrates with electronic health record systems. By reducing manual note-taking, it helps clinicians capture key details while producing clear summaries for patients, and ensures documentation is added to patient records. Abridge emphasizes data security and patient privacy, complies with healthcare regulations, and provides a customizable interface aligned with clinical workflows and patient needs.

Claris Biotherapeutics

Series A in 2024
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

ROME Therapeutics

Series B in 2023
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Abcuro

Series B in 2023
Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Violet Therapeutics

Venture Round in 2023
Violet Therapeutics is a pre-clinical stage biotechnology company focused on drug discovery for central nervous system diseases. The company utilizes innovative platforms that identify, map, and analyze cellular connectomes through barcoded viral tracing, offering insights into cell-cell interactions at a single-cell level. This approach aims to facilitate advancements in the understanding and treatment of neuroinflammation. Co-founded by Mass General Brigham Ventures and researchers from Brigham & Women’s Hospital, Violet Therapeutics is committed to exploring novel therapeutic targets to develop effective treatments for complex neurological conditions.

Mediar Therapeutics

Series A in 2023
Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

CodaMetrix

Series A in 2023
CodaMetrix develops an AI-powered platform for healthcare revenue cycle management. Its platform uses machine learning, deep learning, and natural language processing to autonomously translate clinical notes into billing and diagnostic codes, reducing human workload while maintaining coding accuracy.

Garuda Therapeutics

Series B in 2023
Garuda Therapeutics is a biotechnology company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening blood, bone marrow, immune, and metabolic diseases. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants. Utilizing advanced technologies, including zebrafish, mice, and human-induced pluripotent stem cells, Garuda Therapeutics conducts research to clone and analyze novel genes and mechanisms critical for blood formation. This innovative approach is designed to provide patients with consistent, durable, and HLA-compatible transgene-free blood stem cell therapies, offering rapid and broad access to life-saving treatments.

Amolyt Pharma

Series C in 2023
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

FireCyte Therapeutics

Seed Round in 2023
FireCyte Therapeutics is developing treatments targeting microglia and neuroinflammation for progressive neurodegenerative eye diseases such as glaucoma and age-related macular degeneration.

InStride Health

Venture Round in 2022
InStride Health is an outpatient care platform focused on delivering evidence-based treatment for pediatric anxiety and obsessive-compulsive disorder (OCD). The company offers a tailored virtual care journey that includes individual and group therapy, coaching, and medication management. This comprehensive approach is facilitated by a coordinated team of experienced psychiatrists, therapists, and coaches, ensuring that children and teenagers receive effective and accessible care. InStride Health aims to engage young patients and their families in their treatment, making mental health support both affordable and effective.

Rippl Care

Seed Round in 2022
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Photys Therapeutics

Series A in 2022
Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

Carta Healthcare

Series B in 2022
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.

SwanBio Therapeutics

Series B in 2022
SwanBio Therapeutics is a biotechnology company dedicated to developing innovative therapies for neurological diseases. The firm specializes in genetically defined treatments aimed at addressing various neurological disorders, including adrenomyeloneuropathy (AMN). By focusing on the development and commercialization of its therapeutic technology, SwanBio seeks to provide effective solutions that can significantly improve clinical outcomes for patients affected by such conditions.

DexCare

Series B in 2022
DexCare is a Seattle-based company founded in 2021 that specializes in providing a platform-as-a-service solution for managing health system capacity and demand across various lines of care. The company's platform aims to transform traditional patient-to-provider relationships into scalable digital experiences, thereby increasing revenue from new patients while reducing acquisition costs. By optimizing access to healthcare services, DexCare helps healthcare institutions generate new patients, enhance satisfaction, achieve cost savings, and ensure that patients receive timely and effective care.

Garuda Therapeutics

Series A in 2021
Garuda Therapeutics is a biotechnology company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening blood, bone marrow, immune, and metabolic diseases. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants. Utilizing advanced technologies, including zebrafish, mice, and human-induced pluripotent stem cells, Garuda Therapeutics conducts research to clone and analyze novel genes and mechanisms critical for blood formation. This innovative approach is designed to provide patients with consistent, durable, and HLA-compatible transgene-free blood stem cell therapies, offering rapid and broad access to life-saving treatments.

Amolyt Pharma

Series B in 2021
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

ROME Therapeutics

Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Lyndra Therapeutics

Series C in 2021
Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Affinia Therapeutics

Series B in 2021
Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Carta Healthcare

Series A in 2021
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.

SeQure DX

Venture Round in 2021
SeQure DX is a biotechnology company specializing in genomics diagnostics for CRISPR-based gene editing therapies. It develops technologies that identify potential off-target sites prior to therapy initiation, ensuring comprehensive confirmation of actual edits. This enables safer and more effective gene editing therapeutics development, benefiting both researchers and patients.

Abcuro

Series A in 2021
Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

CustomSurg

Grant in 2020
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

Scorpion Therapeutics

Series A in 2020
Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Walden Biosciences

Series A in 2020
Walden Biosciences, Inc. is a biotechnology company dedicated to developing innovative treatments for individuals suffering from kidney diseases, including chronic kidney disease and acute kidney injury. Founded in 2013 and based in Cambridge, Massachusetts, the company focuses on targeting specific biological mechanisms related to renal health. It specializes in therapies that address suPAR, an inflammatory biomarker linked to kidney function, and Dynamin, an enzyme crucial for maintaining podocyte integrity. By applying a systems-based approach, Walden Biosciences aims to transform the therapeutic landscape for kidney disease, offering targeted treatment options that address both rare and prevalent conditions affecting kidney health.

ZielBio

Series A in 2019
ZielBio is an early-stage biotechnology company based in Charlottesville, Virginia. It identifies novel high-value disease targets and develops therapeutic interventions using its proprietary Zielfind platform, which combines functional high throughput screening with large content data analytics. ZielBio's lead compound, ZB131, is a humanized monoclonal antibody targeting cell surface plectin for cancer treatment.

Lyndra Therapeutics

Series B in 2019
Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Mediar Therapeutics

Seed Round in 2019
Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

QurAlis Corporation

Seed Round in 2018
QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Pykus Therapeutics

Seed Round in 2018
Founded in 2016, Pykus Therapeutics develops a dissolvable intraocular surgical device designed to enhance retinal surgery by reducing patient discomfort. The company's core innovation is a polymer-based hydrogel that replaces the use of intraocular gas during such procedures, eliminating the need for patients to maintain face-down positioning and facilitating quicker recovery.

Lyndra Therapeutics

Series A in 2017
Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Massachusetts Eye and Ear

Acquisition in 2017
Massachusetts Eye and Ear is a specialized hospital located in Boston, Massachusetts, dedicated to the research, education, and treatment of conditions related to the eye and ear. Established in 1824, it provides comprehensive care and innovative solutions for patients with various visual and auditory disorders. The institution is supported by an independent non-profit foundation that raises funds to enhance its mission and operations. Through a combination of clinical care, research initiatives, and educational programs, Massachusetts Eye and Ear aims to advance the understanding and treatment of eye and ear health, making significant contributions to the field.

Health Catalyst

Series D in 2015
Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.

T2 Biosystems

Series D in 2011
T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

T2 Biosystems

Series C in 2010
T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

T2 Biosystems

Series B in 2008
T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Provasculon

Series A in 2008
Provasculon is a biotechnology company founded to leverage a significant discovery made by Dr. Richard Lee and Dr. Vincent Segers at Brigham and Women's Hospital. The company focuses on the development of novel therapeutic proteins, particularly those related to the growth factor Stromal Cell-Derived Factor-1 (SDF-1). Provasculon's lead product is designed to aid in the healing of organs affected by ischemia, specifically targeting heart tissue that has suffered severe ischemic damage. This therapeutic approach aims to restore normal cardiac function, representing a potential advancement in the treatment of ischemic conditions.

Freedom2

Series A in 2007
Freedom2 is a biotechnology company founded nearly a decade ago with a mission to revolutionize tattoo removal. The company specializes in developing permanent tattoo ink removers using its proprietary Particle Encapsulation and Enhancement (P2E) Platform. This platform employs microscopic bioabsorbable pigments encapsulated in biocompatible polymers, forming microencapsulated colored beads that facilitate safe and easy future removal via a single standard laser treatment. Freedom2 aims to provide customers with a more affordable and less painful tattoo removal solution compared to traditional methods.

GlobeImmune

Series B in 2005
GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, specializing in the development of therapeutic products for cancer and infectious diseases utilizing its proprietary Tarmogen platform. Founded in 1995 as Ceres Pharmaceuticals, the company focuses on creating targeted molecular immunotherapies. Its product pipeline includes GS-4774, currently in Phase 2 trials for chronic hepatitis B infection, and GI-6301, aimed at cancers expressing the brachyury protein. Additionally, GlobeImmune is advancing GI-6207 for medullary thyroid cancer and GI-4000 for resected pancreatic cancer, with multiple Phase 2 clinical trials for various other cancers, including non-small cell lung cancer and colorectal cancer. The company is also developing several candidates targeting infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D, which are in preclinical stages. GlobeImmune has established strategic collaborations with notable organizations, enhancing its research and development efforts.

Radianse

Venture Round in 2004
Radianse provides intelligent real-time tracking and situational awareness solutions for businesses. Its software automatically collects and processes live data on assets, recording history and making it accessible via a web-enabled interface. The company aims to deliver accessible, affordable, customized solutions that integrate data sources into real-time actionable intelligence, helping customers manage resources, control costs, increase revenue opportunities, and improve operational efficiency. Radianse has developed algorithms and methodologies to deliver reliable products with high accuracy and performance, protected by multiple patents. Originating from RFID-based monitoring, it now serves clients across industries, including corrections, eldercare, healthcare, and fitness sectors, applying real-time location systems, asset management, IoT, and intelligent enterprise services to optimize processes and throughput.

Carta Healthcare

Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.